Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin Plus Toripalimab With or Without PLND for Bladder-Sparing Treatment in Bladder Cancer
NCT07756008Phase 3Not yet recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Aug 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
A Phase 3 trial of disitamab vedotin, toripalimab in bladder urothelial carcinoma, sponsored by The Second Hospital of Tianjin Medical University. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
bladder urothelial carcinoma
Beyond the preview
Go deeper on NCT07756008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07756008.